Oliver Mikse
机构: Post-Doctoral Fellow, Dana-Farber
每年引用次数
引用次数
引用: 2,376
H-指数: 15
I10-指数 : 16
出版物: 36
OP0307 A NOVEL TARGETED APPROACH TO ACHIEVE IMMUNE SYSTEM RESET: CD45-TARGETED ANTIBODY DRUG CONJUGATES AMELIORATE DISEASE IN PRECLINICAL AUTOIMMUNE DISEASE MODELS AND ENABLE AUTO-HSCT
S. Hyzy , G. Sarma , P. Bhattarai , T. Boitano
Annals of the Rheumatic Diseases 79 190 -191
2020
Variation of the neurofilament medium KSP repeat sub-domain across mammalian species: implications for altering axonal structure.
D. M. Barry , C. Carpenter , C. Yager , B. Golik
The Journal of Experimental Biology 213 ( 1) 128 -136
16
2010
FOXO3 encodes a carcinogen-activated transcription factor frequently deleted in early-stage lung adenocarcinoma.
Oliver R. Mikse , Daniel C. Blake , Nathan R. Jones , Yuan-Wan Sun
Cancer Research 70 ( 15) 6205 -6215
31
2010
Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16Ink4a loss
Michael T. Debies , Shelley A. Gestl , Jessica L. Mathers , Oliver R. Mikse
Journal of Clinical Investigation 118 ( 1) 51 -63
55
2008
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
Esra A. Akbay , Shohei Koyama , Julian Carretero , Abigail Altabef
Cancer Discovery 3 ( 12) 1355 -1363
730
2013
Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC
Jeremy H. Tchaicha , Esra A. Akbay , Abigail Altabef , Oliver R. Mikse
Cancer Research 74 ( 17) 4676 -4684
42
2014
The impact of the MYB-NFIB fusion proto-oncogene in vivo
Oliver R. Mikse , Jeremy H. Tchaicha , Esra A. Akbay , Liang Chen
Oncotarget 7 ( 22) 31681 -31688
6
2016
FOXO3a elicits a pro-apoptotic transcription program and cellular response to human lung carcinogen nicotine-derived nitrosaminoketone (NNK)
Daniel C. Blake , Oliver R. Mikse , Willard M. Freeman , Christopher R. Herzog
Lung Cancer 67 ( 1) 37 -47
22
2010
Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells
J Wang , O Mikse , R G Liao , Y Li
Oncogene 34 ( 17) 2167 -2177
74
2015
Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice
K. Yamanaka , S. Boillee , E. A. Roberts , M. L. Garcia
Proceedings of the National Academy of Sciences of the United States of America 105 ( 21) 7594 -7599
245
2008
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013; 3: 1355–1363. doi: 10.1158/2159-8290
EA Akbay , S Koyama , J Carretero , A Altabef
CD-13-0310.[Europe PMC free article][Abstract][CrossRef][Google Scholar]
88
disease: neurons don’t take all of the blame for ALS
K Yamanaka , S Boillee , EA Roberts , ML Garcia
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013; 3 (12): 1355–1363. doi: 10.1158/2159-8290
EA Akbay , S Koyama , J Carretero , A Altabef
CD-13-0310.[Europe PMC free article][Abstract][CrossRef][Google Scholar]
48
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013; 3 (12): 1355–63. doi: 10.1158/2159-8290
EA Akbay , S Koyama , J Carretero , A Altabef
CD-13-0310
22
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov.(2013) 3: 1355–63. doi: 10.1158/2159-8290
EA Akbay , S Koyama , J Carretero , A Altabef
CD-13-0310
48
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3: 1355-63
EA Akbay , S Koyama , J Carretero , A Altabef
Go to original source... Go to PubMed
15
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3: 1355-63; PMID: 24078774
EA Akbay , S Koyama , J Carretero , A Altabef
5
FoxO3a gene is a target of deletion in mouse lung adenocarcinoma
Christopher R Herzog , Daniel C Blake , Oliver R Mikse , Lubov S Grigoryeva
Oncology Reports 22 ( 4) 837 -843
11
2009
Characterization of Foxo3a as a suppressor of lung adenocarcinoma
Oliver R Mikse
The Pennsylvania State University
1
2011
A Single Dose of a Novel Anti-Human Short Half-Life Engineered CD45-Targeted Antibody-Drug Conjugate (ADC) Is Cytoreductive on Patient-Derived Tumors and Extends Survival Beyond Standards of Care in Multiple Pre-Clinical Models of Hematologic Malignancy
Jennifer L. Proctor , Geoffrey O. Gillard , Oliver Mikse , Leanne Lanieri
Biology of Blood and Marrow Transplantation 26 ( 3)
2020